FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

By Jennie Walters | Sep 21, 2018 | 4:26 PM GMT

Pharming Group N.V. (Euronext:PHARM) said FDA requested another clinical trial of Ruconest conestat alfa as a prophylactic for hereditary angioedema in

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE